Association of UGT1A1*28 polymorphism with the efficacy and toxicity of irinotecan chemotherapy

Chinese Journal of Cancer Prevention and Treatment

Volumn 20, Issue 9, 2013, Pages 717-720

  Zhao, Rong Rong ^a,b   Niu, Zuo Xing ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF JINAN   (China)

Author keywords

Clinical efficacy; Irinotecan; Review literature; Toxicity; UGT1A1*28 polymorphism

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A1 28; IRINOTECAN; UNCLASSIFIED DRUG;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; GENETIC ASSOCIATION; HUMAN; MEDLINE; NEUTROPENIA; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EID: 84886887657     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Zhou CF, Ma T, Su Y, et al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in chinese han patients with gastrointestinal cancer[J]. Anticancer Agents Med Chem, 2013, 13(2): 235-241.
2. Hirose K, Kozu C, Yamashita K, et al. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene [J]. Oncol Lett, 2012, 3(3): 694-698.
3. Takahara N, Nakai Y, Isayama H, et al. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer [J]. Cancer Chemother Pharmacol, 2013, 71(1): 85-92.
4. Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy [J]. Cancer Chemother Pharmacol, 2009, 63(6): 1165-1169.
5. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma [J]. Cancer, 2008, 112(9): 1932-1940.
6. Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial [J]. J Clin Oncol, 2009, 27(25): 4109-4115.
7. The LK, Hashim H, Zakaria ZA, et al. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia[J]. Indian J Med Res, 2012, 136(2): 249-259.
8. Schulz C, Heinemann V, Schalhorn A, et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regiments in metastatic colorectal cancer [J]. World J Gastroenterol, 2009, 15(40): 5058-5066.
9. Mcleod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741 [J]. J Clin Oncol, 2010, 28(20): 3227-3233.
10. Marcuello E, Altés A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer [J]. Br J Cancer 2004, 91(4): 678-682.
11. Sunakawa Y, Ichikawa W, Fujita K, et al. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer [J]. Cancer Chemother Pharmacol, 2011, 68(2): 279-284.
12. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan [J]. J Clin Oncol, 2009, 27(15): 2457-2465.
13. Shulman K, Cohen I, Barnett-Griness O, et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients [J]. Cancer, 2011, 117(14): 3156-3162.
14. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan [J]. J Clin Oncol, 2004, 22(8): 1382-1388.
15. Wang Y, Shen L, Xu N, et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil[J]. World J Gastroenterol, 2012, 18(45): 6635-6644.
16. Martinez-Balibrea E, Abad A, Martínez-Cardús A, et al. UGT1A1 and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy [J]. Br J Cancer, 2010, 103(4): 581-589.
17. Kweekel DM, Gelderblom H, Van der Straaten T, et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a dutch colorectal cancer group study [J]. Br J Cancer, 2008, 99(2): 275-282.
18. Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 *28/*6 polymorphisms [J]. Jpn J Clin Oncol, 2011, 41(4): 477-482.
19. Onoue M, Terada T, Kobayashi M, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients [J]. Int J Clin Oncol, 2009, 14(2): 136-142.
20. Hu ZY, Yu Q, Zhao YS, et al. Dose-dependent association between UGT1A1 *28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis [J]. Eur J Cancer, 2010, 46(10): 1856-1865.
21. Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial [J]. J Clin Oncol, 2009, 27(33): 5519-5528.
22. 2010, 30(10): 870-874.
23. 2011, 46(12): 888-891.
24. Jo JC, Lee JL, Ryu MH, et al. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer [J]. Br J Cancer, 2012, 106(10): 1591-1597.
25. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2010, 28(5): 866-871.
26. Marcuello E, Páez D, Paré L, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer [J]. Br J Cancer, 2011, 105(1): 53-57.
27. Freyer G, Duret A, Milano G, et al. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study [J]. Anticancer Res, 2011, 31(1): 359-366.
28. Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms [J]. Cancer Sci, 2011, 102(10): 1868-1873.